EPCAM and carcinoma: We previously reported that about 66% healthy subjects (n = 47) had aneuploid EpCAM−/vimentin− null ECs detected in peripheral blood with an average of 2.8 cells compared with 100% in all carcinoma patients (n = 133) with an average of 8.8 cells, and none of EpCAM+ or Vim+ circulating CD31+ cells were detected in healthy donors [11].